Saltar al contenido
Merck

Arachidonic acid induces brain endothelial cell apoptosis via p38-MAPK and intracellular calcium signaling.

Microvascular research (2014-05-08)
Justin Evans, YooSeung Ko, Wilmer Mata, Muhammad Saquib, Joel Eldridge, Aaron Cohen-Gadol, H Anne Leaver, Shukun Wang, Maria Teresa Rizzo
RESUMEN

Arachidonic acid (AA), a bioactive fatty acid whose levels increase during neuroinflammation, contributes to cerebral vascular damage and dysfunction. However, the mode of injury and underlying signaling mechanisms remain unknown. Challenge of primary human brain endothelial cells (HBECs) with AA activated a stress response resulting in caspase-3 activation, poly(ADP-ribose) polymerase cleavage, and disruption of monolayer integrity. AA also induced loss of mitochondrial membrane potential and cytochrome c release consistent with activation of intrinsic apoptosis. HBEC stimulation with AA resulted in sustained p38-MAPK activation and subsequent phosphorylation of mitogen-activated protein kinase activated protein-2 (MAPKAP-2) kinase and heat shock protein-27 (Hsp27). Conversely, other unsaturated and saturated fatty acids had no effect. Pharmacological and RNA interference-mediated p38α or p38β suppression abrogated AA signaling to caspase-3 and Hsp27, suggesting involvement of both p38 isoforms in AA-induced HBEC apoptosis. Hsp27 silencing also blocked caspase-3 activation. AA stimulated intracellular calcium release, which was attenuated by inositol 1,4,5-trisphosphate (IP3) receptor antagonists. Blockade of intracellular calcium release decreased caspase-3 activation, but had no effect on AA-induced p38-MAPK activation. However, inhibition of p38-MAPK or blockade of intracellular calcium mobilization abrogated AA-induced cytochrome c release. AA-induced caspase-3 activation was abrogated by pharmacological inhibition of lipooxygenases. These findings support a previously unrecognized signaling cooperation between p38-MAPK/MAPKAP-2/Hsp27 and intracellular calcium release in AA-induced HBEC apoptosis and suggest its relevance to neurological disorders associated with vascular inflammation.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Ácido oleico, technical grade, 90%
Sigma-Aldrich
Palmitic acid, ≥99%
Sigma-Aldrich
Ácido linoleico, ≥98%
Sigma-Aldrich
Stearic acid, Grade I, ≥98.5% (capillary GC)
Sigma-Aldrich
2-Aminoethyl diphenylborinate, 97%
Sigma-Aldrich
Ácido oleico, BioReagent, suitable for cell culture
Sigma-Aldrich
Ácido linoleico, liquid, BioReagent, suitable for cell culture
Sigma-Aldrich
Ácido oleico, natural, FCC
Sigma-Aldrich
Palmitic acid, BioXtra, ≥99%
Sigma-Aldrich
Myristic acid, Sigma Grade, ≥99%
Sigma-Aldrich
Stearic acid, ≥95%, FCC, FG
Sigma-Aldrich
Palmitic acid, ≥98%, FCC, FG
Sigma-Aldrich
Ácido linoleico, technical, 58-74% (GC)
Sigma-Aldrich
Ácido oleico, ≥99% (GC)
USP
Stearic acid, United States Pharmacopeia (USP) Reference Standard
USP
Palmitic acid, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Palmitic acid, ≥98% palmitic acid basis (GC)
Sigma-Aldrich
Stearic acid, reagent grade, 95%
Sigma-Aldrich
Myristic acid, ≥95%, FCC, FG
Sigma-Aldrich
Nordihydroguaiaretic acid, ≥97.0% (HPLC)
Sigma-Aldrich
Palmitic acid, natural, 98%, FG
Sigma-Aldrich
Myristic acid, natural, ≥98.5%, FG
Supelco
Stearic acid, analytical standard
Supelco
Ácido oleico, analytical standard
Supelco
Palmitic acid, analytical standard
Supelco
Ácido linoleico, analytical standard
Sigma-Aldrich
Myristic acid, ≥98.0% (GC)
Supelco
Stearic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Palmitic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Myristic acid, analytical standard